| Objective To evaluate the efficacy and toxicity of combination therapy of oxaliplatin in combination with capecitabine regimen in patients with advanced gastric cancer.Methods The clinical data of 65 patients with advanced gastric cancer(stage Ⅱb to IIIc) who were admitted to the first Affiliated Hospital of Anhui Medical University from July 2011 to September 2012 were retrospectively analyzed.All the patients were divided into the neoadjuvant chemotherapy group(33 cases) and the surgery alone group(32 cases). The efficacy of radical resection, postoperative complication rate, overall survival of the 2 groups were compared.The count data and the measurement data were analyzed using the chisquare test and the t test, respectively.Results The age, gender,smoking and drinking history,TNM stage and the site of the tumor, with no significant difference between the 2 group.All patients in the experimental group after symptomatic treatment of chemotherapy side effects were significantly alleviated.Among the patients in the experimental group CR in 1 cases, PR 15, SD 14, PD (4 cases), and the total RR and ORR rate were 48.5% and 90.9%, and IIB period RR rate was 29%, type IIIA stage RR rate was 28.6%, type ⅢB stage RR rate was 63.6%, stage IIIC RR rate was 60%, P<0.05.The numbers of patients who received R0 and Rl resection in the neoadjuvant chemotherapy group were 32 and 1, which were significantly different from 24 and 8 in the surgery alone group (2=4.861, P<0.05).The number of lymph node metastasis in the treatment group(4.55±1.48)was significantly lower than that in the control arm(6.38±2.27, t=-3.838, P<0.05).There were no significant differences in the number of postoperative complication case(3 cases VS.3 cases)and the number of lymph node dissection(21.24±2.67 VS.20.19±2.71)between the two groups(P>0.05).The average volume of peri-operative bleeding in the treatment group(434.29±86.64ml)was significantly higher than that in the control arm(190.97±47.91ml, P<0.05). The survival analysis indicated that the median overall survival was longer in the neoadjuvant chemotherapy group (23.5 months) in comparison with this in the surgery along group (17.7 months), but no significant differences were found (P>0.05)Conclusions The combination neoadjuvant chemotherapy regimen of oxaliplatin and capecitabine can be effectively. Patients tolerance and compliance are satisfactory. It can improve in patients with advanced gastric cancer the RO resection rate, reduce lymph node metastasis and improve survival. The ⅢB stage RR rate and type ⅢC stage RR rate were higher than the ⅡB stage RR rate and type ⅢA stage RR rate, but there was no statistically significant difference.Patients with stage IIIB and IIIC gastric cancer have a potential for a bigger crowd for neoadjuvant chemotherapy. |
PDF Full Text Request